ADVISORY/At AACR Meeting: LumiCyte to Showcase Technology that Surpasses Existing Serum Protein-Mapping Benchmarks.

News & Assignment Editors/Health & Medical Writers

BIOWIRE2K

AACR Meeting

ADVISORY...for Sunday-Wednesday (April 7-10)

--(BW HealthWire)

 LumiCyte Will Display Their Revolutionary SELDI-Based Biotechnology
        Services at Booth #714 at the AACR 93rd Annual Meeting
                    in San Francisco on April 7-10

WHO     LumiCyte, Inc. -- a biotechnology company that enables the
        early diagnosis of cancer and drives the evolution of drug
        development.
        Dr. Bill Hutchens -- Founder and CEO of LumiCyte and inventor
        of the SELDI proteomics technology.

WHAT    As an exhibitor at the AACR 93rd Annual Meeting, at the
        Moscone Convention Center in San Francisco, Calif., LumiCyte
        will showcase its SELDI-based biotechnology services and
        announce that it has achieved an exciting new level of
        protein-mapping capabilities as benchmarked by today's most
        sophisticated technologies.

          LumiCyte generates high-information content protein maps with
        unprecedented speed, sensitivity and accuracy. Analysis of
        these maps with LumiCyte's proprietary suite of neural network
        and pattern recognition software enables:
              --  Early detection of disease onset
              --  More effective classification of disease
              --  More accurate monitoring of disease progression
              --  Early indication of patient-specific response to
                therapy

          LumiCyte's biochip products are low cost, distributable sample
        collection and diagnostic devices that are being used in
        support of clinical trials.

WHEN:   April 7-10, 2002

WHERE:  Moscone Convention Center, Booth 714, San Francisco, Calif.

INTERVIEWS:     Dr. Bill Hutchens will be available on April 8-10 by
                appointment only. Hutchens and the team at LumiCyte
                pioneered the development of advanced biochips and
                informatics technologies to generate comprehensive
                human serum protein maps. To schedule a meeting,
                contact either:

CONTACT: J.P. Carr                  Louise Bono
         Sterling Hager             LumiCyte, Inc.
         415/591-8402               510/413-9224
         [e-mail]       [e-mail]

LumiCyte: The advanced, proprietary biotechnology services offered exclusively by Fremont, Calif.-based LumiCyte, Inc. allow pharmaceutical and biotechnology companies to optimize drug development, and enable physicians to offer more individualized and accurate care to their patients. www.lumicyte.com

LumiCyte combines THREE core technologies to offer contract services that remove the inefficiencies found today in the pharmaceutical and biotechnology industries' multi-billion dollar drug development process:

1. Advanced SELDI Biochips that feature the most sensitive,

accurate and comprehensive protein-mapping capabilities

available.

2. Patented and proprietary Data Analysis Software that was

developed to identify patterns within the high-resolution

protein topographical maps produced by the LumiCyte Biochip.

3. The BioPhore Knowledgebase(TM), an open-architecture

information platform that integrates our disease-specific

protein information with other genomics, proteomics and

clinical information. The BioPhore Knowledgebase currently

holds records for over 2200 human serum proteins with 180

descriptors each.